Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Short Title: S1501

Enrollment Status: Recruiting

NCT #: NCT03418961

Specialty Area: Oncology

Condition Studied: Metastatic HER-2+ Breast Cancer

Age Groups: Adult; Older Adult

Phase: Not Applicable

Study Information

Summary / Purpose

To understand heart health in people with HER2-positive breast cancer that has spread and who are receiving standard HER2-targeted therapy. Some cancer treatments can affect the heart, and this study is observing heart function over time and collecting health information to help doctors learn what factors might increase the risk of heart problems during treatment. The goal of the study is to improve future care and help manage heart health for patients receiving these therapies.

Study Type: Observational

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with early stage (stage I-III) hormone receptor-positive breast cancer
Completed surgery and standard therapy and are suitable for hormone therapy

What's Involved

Participation in the study will include:

Observation for up to 108 weeks
Providing health information

Principal Investigator

Lee Schwartzberg, MD

Oncology

A Member of

(775) 982–5000

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT03418961

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews